1. Home
  2. PEBK vs SGHT Comparison

PEBK vs SGHT Comparison

Compare PEBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peoples Bancorp of North Carolina Inc.

PEBK

Peoples Bancorp of North Carolina Inc.

HOLD

Current Price

$44.23

Market Cap

218.4M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$5.41

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEBK
SGHT
Founded
1912
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.4M
235.0M
IPO Year
2012
2021

Fundamental Metrics

Financial Performance
Metric
PEBK
SGHT
Price
$44.23
$5.41
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
27.8K
132.5K
Earning Date
04-20-2026
05-06-2026
Dividend Yield
2.58%
N/A
EPS Growth
21.48
28.16
EPS
0.80
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
$53.63
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.81
$3.11
52 Week High
$45.78
$9.24

Technical Indicators

Market Signals
Indicator
PEBK
SGHT
Relative Strength Index (RSI) 61.63 63.44
Support Level $38.84 $4.76
Resistance Level $45.78 $5.66
Average True Range (ATR) 1.27 0.27
MACD -0.06 0.05
Stochastic Oscillator 62.82 94.80

Price Performance

Historical Comparison
PEBK
SGHT

About PEBK Peoples Bancorp of North Carolina Inc.

Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: